Paracetamol or ibuprofen treatment outcomes in preterm infants with patent ductus arteriosus: a retrospective cohort analysis.
This retrospective cohort study was conducted in the neonatal intensive care unit of a tertiary care center. The population consisted of 60 preterm infants admitted with echocardiographically confirmed patent ductus arteriosus. The overall PDA incidence was 2.8% based on 60/2154 cases. Patients received pharmacological treatment with intravenous paracetamol or ibuprofen. Clinical improvement after first-line treatment was reported in 77% of the cohort. Ductal closure after first-line treatment occurred in 83.3% of patients. Most follow-up assessments were completed within 3 days. Predictors of successful closure included gestational age of 28 weeks or greater, with an OR = 5.9 and 95% CI: 1.7-20.2. Antenatal corticosteroid exposure showed an OR = 1.2 with 95% CI: 1.0-1.6. Overall mortality was 35%. Infants under 28 weeks had increased mortality with an OR = 5.0 and 95% CI: 2.4-10.3. Clinical improvement and echocardiographic closure were associated with reduced mortality, with OR = 3.7 and OR = 4.5 respectively. Safety data regarding adverse events were not reported. Serious adverse events were not reported. Discontinuations were not reported. Tolerability was not reported. The observational design limits causal inference. Systematic echocardiographic screening in high-risk neonates should be considered. This study was published as an abstract. Funding or conflicts were not reported.